Quantcast

Latest Protease inhibitor Stories

2008-09-08 09:00:52

BRISBANE, Calif., Sept. 8 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced that Steven B. Porter, M.D., Ph.D., Chief Medical Officer of InterMune, will present at the Robert W. Baird & Co. Small Cap Healthcare Conference in New York on September 10, 2008 at 10:30 a.m. EDT. To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at http://www.intermune.com/. The...

2008-09-02 09:00:43

BRISBANE, Calif., Sept. 2 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced that InterMune has earned a $15 million development milestone under its development collaboration with Roche for the hepatitis C virus (HCV) NS3 protease inhibitor compound ITMN-191 (referred to as R7227 at Roche), currently in a Phase 1b clinical trial in combination with Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin). Under the terms of their 2006 collaboration agreement, the clinical...

2008-08-29 12:01:17

BRISBANE, Calif., Aug. 29 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced that Daniel G. Welch, Chairman, CEO and President of InterMune, will present at the Thomas Weisel Partners Healthcare Conference in Boston on September 4, 2008 at 10:55 a.m. EDT. To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at http://www.intermune.com/. The company recommends logging on...

2008-08-19 09:00:17

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Company has reached agreement with U.S. and E.U. regulatory authorities to proceed with the REALIZE trial, a pivotal Phase 3 clinical trial with the hepatitis C virus (HCV) protease inhibitor telaprevir in combination therapy for patients with chronic HCV infection who failed to achieve a sustained viral response (SVR) with prior therapy. The trial will be conducted in the U.S. and E.U. and will enroll approximately...

2008-07-30 18:00:54

BRISBANE, Calif., July 30 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced that Daniel G. Welch, Chairman, CEO and President of InterMune, will present at the BMO Capital Markets 2008 Focus on Healthcare Conference in New York on August 6, 2008 at 10:00 a.m. EDT. To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at http://www.intermune.com/. The company recommends...

2008-07-29 09:01:15

CAMBRIDGE, Mass., July 29 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. , a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today announced that it has initiated a first-in-man study of IDX184 under a United States investigational new drug (IND) application. IDX184 is a once-daily, oral nucleotide prodrug polymerase inhibitor for the treatment of chronic hepatitis C. Today, Idenix also...

2008-06-18 09:01:17

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Freda C. Lewis-Hall, M.D. as Executive Vice President, Medicines Development. Dr. Lewis-Hall joins Vertex from Bristol-Myers Squibb, Incorporated, and has extensive leadership experience across multiple functional areas in the pharmaceutical industry. At Vertex, Dr. Lewis-Hall will be responsible for Regulatory Affairs, Clinical and Non-clinical Development, Medical Affairs and Commercial Development. Dr....

2008-06-16 09:01:19

NanoViricides, Inc. (OTC BB: NNVC.OB), (the "Company") said that its lead anti-HIV drug candidate demonstrated markedly superior survival results in the test animals when compared to those animals given the anti-HIV "combo cocktail" in a double-blind animal study. The three-drug combo "cocktail" used for comparison is one of the most frequently used triple combination therapies in humans. The Company reported that the best nanoviricide anti-HIV drug candidate improved total hours of...

a0aadd03628cea11ab724242333c3eee1
2008-01-29 11:59:39

The combined supercomputing power of the UK and US "Ëœnational grids' has enabled UCL (University College London) scientists to simulate the efficacy of an HIV drug in blocking a key protein used by the lethal virus. The method "“ an early example of the Virtual Physiological Human in action "“ could one day be used to tailor personal drug treatments, for example for HIV patients developing resistance to their drugs.The study, published online today in the Journal of the...

2006-08-13 15:47:57

By Maggie Fox, Health and Science Correspondent TORONTO (Reuters) - Simpler drug combinations can control the AIDS virus well, researchers said on Sunday in several reports that will help in trying to mix and match nearly two dozen different HIV drugs in lifesaving cocktails. The reports published in the Journal of the American Medical Association, and presented to the International AIDS Conference in Toronto, show that simplified drug regimens can be safe and effective, and safely...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related